Helus Pharma
Market cap $575M 79.8M shares (vendor count, Nov 18, 2026) × $7.20 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page
Pipeline (3 active programs)
CYB003
CYB004
HLP004Discontinued (1)
- SPL026 — Major Depressive Disorder
Capital (as filed)
- As stated in coverage
- $171M cash, runway 4Q 2027 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
- 2026-06-24 FWP · Pricing term sheet
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (15)
- 2026-11-17 UPDATE: Helus Pharma (HELP) - The Coin Lands Heads, and the Stock Sells Off Anyway 🔒 Paid
- 2026-11-14 UPDATE: Helus Pharma (HELP) - The Smart Money Thins Out Before the Coin Flip 🔒 Paid
- 2026-10-28 UPDATE: Helus Pharma (HELP) - The Founders Leave the Room 🔒 Paid
- 2026-08-15 UPDATE: Helus Pharma (HELP) - A Permanent CEO, a Clean DDI Study, and 11 Million New Shares 🔒 Paid
- 2026-07-21 UPDATE: Helus Pharma (HELP) - APPROACH Enrollment Done, The Binary Event Is Now a Data Question 🔒 Paid
- 2026-06-29 UPDATE: Helus Pharma (HELP) - The +35% Rip, the Definium Footnote, and EMBRACE Enters the Chat 🔒 Paid
- 2026-06-24 UPDATE: Helus Pharma (HELP) - The Dilution Lands, And It’s Not the ATM 🔒 Paid
- 2026-05-16 UPDATE: Helus Pharma (HELP) - Point72 Trims, Sirenia Arrives, Stock Bleeds 🔒 Paid
- 2026-04-27 UPDATE: Helus Pharma (HELP) - Cola Gets the Boot, Trump Signs the EO, Millennium Doubles Down 🔒 Paid
- 2026-03-28 UPDATE: Helus Pharma (HELP) - Izzy Englander Buys the Dip 🔒 Paid
- 2026-03-07 UPDATE: Helus Pharma (HELP) - The Pooled Data Trick and the $5.25 Reality Check 🔒 Paid
- 2026-02-28 UPDATE: Helus Pharma (HELP) - The Big Pharma Makeover is Complete 🔒 Paid
- 2026-02-21 UPDATE: Helus Pharma (HELP) - The Smart Money Tug-of-War & Peer-Reviewed Receipts 🔒 Paid
- 2026-02-14 UPDATE: Helus Pharma (HELP): The Big Guns Arrive 🔒 Paid
- 2026-01-16 Helus Pharma (HELP), formerly Cybin (CYBN): Scientific Deep Dive for HLP003 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (15 calls)
Every verdict Biotech Distilled has published on Helus Pharma, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-01-16 Watch Helus Pharma (HELP), formerly Cybin (CYBN): Scientific Deep Dive for HLP003 and Pipeline Products The company is a leveraged binary bet on FDA acceptance of psychedelic trial designs with a terrifying 1:1 cash-to-burn ratio; wait for ATM dilution to depress the price before entering.
- 2026-02-14 Watch UPDATE: Helus Pharma (HELP): The Big Guns Arrive Point72's 6.2% stake and Michael Cola's commercial CEO appointment de-risk the business side, but the Dilution Gap and functional unblinding risk remain; watch for HLP004 data reaction before acting.
- 2026-02-21 Buy speculative UPDATE: Helus Pharma (HELP) - The Smart Money Tug-of-War & Peer-Reviewed Receipts OrbiMed's arrival and Nature Medicine publication of the DMT mechanism upgrade scientific conviction, but the imminent HLP004 data readout is the tie-breaker; trade the volatility but respect the dilution risk.
- 2026-02-28 Hold UPDATE: Helus Pharma (HELP) - The Big Pharma Makeover is Complete Former Pfizer CMO joining the board reinforces M&A appeal and regulatory de-risking, but the HLP004 data readout remains the imminent catalyst before any position change.
- 2026-03-07 Avoid UPDATE: Helus Pharma (HELP) - The Pooled Data Trick and the $5.25 Reality Check HLP004 Phase 2 data was massaged by pooling active and placebo arms to hide weak remission differentiation, fundamentally breaking the HLP004 thesis and making the HLP003 Phase 3 risk profile radioactive.
- 2026-03-28 Watch UPDATE: Helus Pharma (HELP) - Izzy Englander Buys the Dip Millennium Management's 4.8% stake alongside Point72 and OrbiMed signals blue-chip institutional conviction in the M&A/event-driven thesis, reducing catastrophic-zero risk before the Q4 2026 readout.
- 2026-04-27 Watch UPDATE: Helus Pharma (HELP) - Cola Gets the Boot, Trump Signs the EO, Millennium Doubles Down The Executive Order mandating prioritized FDA review and DEA rescheduling for BTD psychedelics is the biggest regulatory tailwind ever for the sector, but the +24% rip already prices it in and CEO churn 8 months before the binary readout warrants caution on entry.
- 2026-05-16 Watch UPDATE: Helus Pharma (HELP) - Point72 Trims, Sirenia Arrives, Stock Bleeds Point72 trimming from 6.2% to 1.4% materially weakens the 'Adults in the Room' sponsorship thesis, while the unknown Sirenia replacement and a vacant permanent CEO seat keep the risk/reward ambiguous.
- 2026-06-24 Watch UPDATE: Helus Pharma (HELP) - The Dilution Lands, And It's Not the ATM The $50M bought deal at a 4.7% discount cleanly addresses the Dilution Gap and signals real institutional demand, but post-raise digestion and a still-vacant permanent CEO seat argue for waiting before entering.
- 2026-06-29 Speculative buy speculative UPDATE: Helus Pharma (HELP) - The +35% Rip, the Definium Footnote, and EMBRACE Enters the Chat The dilution setup has substantially played out with the $50M bought deal cleared, EMBRACE Phase 3 disclosed with a 2028 NDA target, and the institutional roster sized in; the asymmetric binary setup is now legible, though chasing $6.88 is not the trade.
- 2026-07-21 Speculative buy speculative UPDATE: Helus Pharma (HELP) - APPROACH Enrollment Done, The Binary Event Is Now a Data Question APPROACH enrollment completed ahead of schedule at 223 patients with 1:1 randomization, retiring enrollment risk and confirming the Q4 binary event is on the rails, though chasing $8.10 on mechanical re-rating is not the trade.
- 2026-08-15 Speculative buy speculative UPDATE: Helus Pharma (HELP) - A Permanent CEO, a Clean DDI Study, and 11 Million New Shares The permanent CEO hire (ex-Intra-Cellular President) and clean DDI study retire the two remaining execution risk flags, but the +48% move to $11.99 has compressed the asymmetry and an 18% share-count increase via equity comp warrants caution on new entries.
- 2026-10-28 Speculative buy speculative UPDATE: Helus Pharma (HELP) - The Founders Leave the Room Founders stepping back to independent roles and a banker becoming independent Chair completes the Big Pharma Makeover governance transition, reinforcing M&A appeal ahead of the Q4 readout, though the ATM remains live and the entry at $10.52 still requires a strong effect size.
- 2026-11-14 Hold UPDATE: Helus Pharma (HELP) - The Smart Money Thins Out Before the Coin Flip Millennium trimming from 5.7% to 1.4% (following Point72's similar exit) strips the institutional sponsorship anchor from the thesis, while insider equity comp has grown the share count 55% since March; with the readout weeks away, holders should size for a d≈0.4 outcome being survivable rather than adding.
- 2026-11-17 Speculative buy speculative UPDATE: Helus Pharma (HELP) - The Coin Lands Heads, and the Stock Sells Off Anyway APPROACH Phase 3 hit every endpoint with a clinically meaningful 7.6-point MADRS gap (d=0.65) and durability to Week 12, retiring first-pivotal clinical risk; the -13.5% sell-the-news drop to $7.67 offers a better entry on a de-risked asset ahead of EMBRACE replication in 4Q 2027.
- Long call · opened Feb 23, 2026 at $6.73 · closed Mar 9, 2026 (flipped bearish (avoid)) at $5.52 · -18.0% vs XBI +0.1%
- Avoid call · opened Mar 9, 2026 at $5.52 · closed Mar 30, 2026 (downgraded to WATCH from avoid) at $4.32 · -21.7% vs XBI -6.6%
- Long call · opened Jun 30, 2026 at $6.61 · +8.9% vs XBI -8.2% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (7 quotes from 7 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“The Company expects to report topline results from the EMBRACE trial in 4Q 2027. 2,3 EXTEND is the ongoing long-term extension study which will provide additional data on long-term safety, durability of effect, and the potential role of redosing.”
matched to HLP003 · topline data
-
-
-
“Provide topline efficacy data readout from the first Phase 3 study, APPROACH, in Q4 2026.”
matched to HLP003 · topline data
-
-
-
“The Company continues to anticipate reporting topline data from its Phase 3 APPROACH pivotal study of HLP003 in major depressive disorder in Q4 2026.”
matched to HLP003 · topline data
-
-
-
“The Company continues to anticipate reporting topline data from its Phase 3 APPROACH pivotal study of HLP003 in major depressive disorder in Q4 2026.”
matched to HLP003 · topline data
-
-
-
“The Company reiterated that HLP003 APPROACH Phase 3 topline data readout is on track for Q4 2026 1,2 and provided an overview of the competitive landscape and commercial opportunity in the adjunctive treatment of MDD.”
matched to HLP003 · topline data
-
-
-
“APPROACH has completed enrollment, and the study is on track for topline data readout in Q4 2026. 1,2”
matched to HLP003 · topline data
-
-
-
“Provide topline efficacy data readout from the first Phase 3 study, APPROACH, in Q4 2026.”
matched to HLP003 · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (71)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 1, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 2026ReleaseHelus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder→ BD updateSummary on the 6-K
- Nov 16, 2026ReleaseHelus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights→ BD updateSummary on the 6-K
- Nov 16, 20266-KForeign issuer report · EX-99.1→ BD updateSummary on the 6-K
- Nov 16, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1→ BD updateSummary on the 6-K
- Nov 16, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1→ BD updateThe APPROACH Phase 3 coin flip has landed — HLP003 beat placebo on both primary and key secondary endpoints with p<0.0001, but the Phase 3 effect size (d=0.653) came in well below the Phase 2's d=2.15, and HELP is down -13.5% on what most would read as a positive readout.
- Nov 15, 2026ReleaseHelus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026→ BD updateSummary on the 6-K of Nov 16, 2026
- Nov 13, 20266-KForeign issuer report · EX-99.1→ BD updateHelus Pharma's Q2 FY2027 earnings confirm the APPROACH Phase 3 data is functionally imminent — only ~$2.9M in estimated remaining spend — while the ATM executed at a surprising $13.30/share average, Millennium has quietly trimmed to 1.4%, and the stock has bled -15.7% since the October founders-exit update.
- Nov 6, 20266-KForeign issuer report · EX-99.1
- Nov 3, 2026ReleaseHelus Pharma to Participate in the Guggenheim Healthcare Innovation Conference
- Nov 3, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Oct 27, 2026ReleaseHelus Pharma Announces Co-Founders’ Transition from Executive Leadership as Company Advances Toward Next Stage of Development→ BD updateSummary on the 6-K
- Oct 27, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1→ BD updateBoth Helus co-founders just stepped back from executive roles two months before the APPROACH Phase 3 readout — the move can be read as a clean CEO handoff to Halstead, or as founders quietly stepping aside ahead of a binary event.
- Oct 21, 2026ReleaseHelus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026
- Oct 21, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Oct 15, 2026ReleaseHelus Pharma Appoints Dr. Suresh Durgam to Board of Directors
- Oct 15, 20266-KForeign issuer report · EX-99.1
- Oct 8, 2026ReleaseHelus Pharma to Host Investor Presentation on October 21, 2026
- Oct 8, 20266-KForeign issuer report · EX-99.1
- Oct 5, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Oct 2, 20266-KForeign issuer report · EX-99.1
- Oct 1, 2026ReleaseHelus Pharma Announces Completion of Legal Name Change
- Oct 1, 20266-KForeign issuer report · EX-99.1
- Sep 23, 20266-KForeign issuer report · EX-99.1
- Sep 22, 2026ReleaseHelus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
- Sep 22, 20266-KForeign issuer report · EX-99.1
- Sep 21, 2026ReleaseHelus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026BD extracted 1 program update from this document → HELP pipeline
- Sep 21, 2026ReleaseHelus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
- Sep 21, 20266-KForeign issuer report · EX-99.1
- Sep 10, 2026ReleaseHelus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York
- Sep 10, 20266-KForeign issuer report · EX-99.1
- Sep 9, 2026SCHEDULE 13DActivist / >5% holder (13D)
- Sep 9, 2026SCHEDULE 13DActivist / >5% holder (13D)
- Sep 9, 2026ReleaseHelus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York
- Sep 9, 20266-KForeign issuer report · EX-99.1
- Sep 3, 2026ReleaseHelus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York
- Sep 3, 20266-KForeign issuer report · EX-99.1
- Aug 19, 20266-KForeign issuer report · EX-99.1
- Aug 18, 2026ReleaseHelus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board
- Aug 18, 20266-KForeign issuer report · EX-99.1
- Aug 14, 2026ReleaseHelus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business HighlightsBD extracted 1 program update from this document → HELP pipeline
- Aug 14, 20266-KForeign issuer report · EX-99.1
- Aug 11, 20266-KForeign issuer report · EX-99.1
- Aug 10, 2026ReleaseHelus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston
- Aug 3, 2026ReleaseHelus Pharma Appoints Michael Halstead as Chief Executive Officer
- Aug 3, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Jul 21, 2026ReleaseHelus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
- Jul 21, 20266-KForeign issuer report · EX-99.1
- Jul 16, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Jun 29, 2026ReleaseHelus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
- Jun 29, 20266-KForeign issuer report · EX-99.1
- Jun 29, 202640-FAnnual report (Canadian)
- Jun 25, 2026ReleaseHelus Pharma™ Announces Closing of US$50 Million Underwritten Offering
- Jun 25, 20266-KForeign issuer report · EX-99.1
- Jun 25, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Jun 24, 2026ReleaseHelus Pharma™ Announces US$50 Million Underwritten Offering
- Jun 24, 2026ReleaseHelus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
- Jun 24, 2026FWPFree writing prospectus (offering terms)
- Jun 11, 2026ReleaseHelus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
- Jun 11, 20266-KForeign issuer report · EX-99.1
- Jun 1, 2026ReleaseHelus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
- Jun 1, 20266-KForeign issuer report · EX-99.1
- May 4, 20266-KForeign issuer report · EX-99.1
- Apr 30, 20266-KForeign issuer report · EX-99.1
- Apr 28, 20266-KForeign issuer report · EX-99.1
- Apr 23, 20266-KForeign issuer report · EX-99.1
- Apr 20, 20266-KForeign issuer report · EX-99.1
- Apr 20, 20266-KForeign issuer report · EX-99.1
- Apr 16, 20266-KForeign issuer report · EX-99.1
- Mar 12, 20266-KForeign issuer report · EX-99.1
- Mar 5, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Mar 5, 20266-KForeign issuer report
19 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD updateSummary on the 6-K
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD updateSummary on the 6-K
- Nov 12, 2026SCHEDULE 13G/A13G amendment
- Nov 12, 2026SCHEDULE 13G/A13G amendment
- Sep 1, 2026S-8Employee plan registration
- Sep 1, 2026DForm D (exempt offering)
- Aug 19, 2026DForm D (exempt offering)
- Aug 19, 2026DForm D (exempt offering)
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 12, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 16, 2026DForm D (exempt offering)
- Jul 16, 2026DForm D (exempt offering)
- Jun 25, 2026SUPPLSUPPL
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 22, 2026SCHEDULE 13G/A13G amendment
- Apr 10, 2026SCHEDULE 13GPassive >5% holder (13G)
- Mar 26, 2026SCHEDULE 13GPassive >5% holder (13G)
- Mar 23, 2026DForm D (exempt offering)